404
E. R. T. Tiekink
48. Lewis, G.R., Steele, G., McBride L., Florence, A.J., Kennedy, A.R., Shankland, N., David,
W.I.F., Shankland, K., Teat, S.J.: Hydrophobic versus hydrophilic: ionic competition in
remacemide salt structures. Cryst. Growth Des. 5, 427–438 (2005)
49. Wardell, J.L., Wardell, S.M.S.V., Tiekink, E.R.T.: A kryptoracemic salt: 2-{[2,8bis(trifluoromethyl)quinolin-4-yl](hydroxy)methyl}piperidin-1-ium
(+)-3,3,3-trifluoro-2methoxy-2-phenylpropanoate. Acta Crystallogr. E57, 872–877 (2016)
50. Jotani, M.M., Wardell, J.L., Tiekink, E.R.T.: Crystal structure and Hirshfeld analysis of the
kryptoracemate: bis(mefloquinium) chloride p-fluorobenzenesulphonate. Z. Kristallogr. Cryst.
Mater. 231, 247–255 (2016)
51. Nevin, R.L.: A serious nightmare: psychiatric and neurologic adverse reactions to mefloquine
are serious adverse reactions. Pharmacol. Res. Perspect 5, e00328 (2017)
52. Engwerda, A.H.J., Maassen, R., Tinnemans, P., Meekes, H., Rutjes, F.P.J.T., Vlieg, E.: Attritionenhanced deracemization of the antimalaria drug mefloquine. Angew. Chem. Int. Ed 58, 1670–
1673 (2019)
53. Haleblian, J., McCrone, W.: Pharmaceutical applications of polymorphism. J. Pharm. Sci 58,
911–929 (1969)
54. Gavezzotti, A., Filippini, G.: Polymorphic forms of organic crystals at room conditions:
thermodynamic and structural implications. J. Am. Chem. Soc 117, 12299–12305 (1995)
55. Price, S.L.: Is zeroth order crystal structure prediction (CSP_0) coming to maturity? What
should we aim for in an ideal crystal structure prediction code? Faraday Discuss 211, 9–30
(2018)
56. Suresh, S., Periasamy, M.: Synthesis of cis-2-aryl-3-pyrrolidine carboxylic esters via diastereoselective cyclization of γ-imino esters using a TiCl 4 /Et 3 N reagent system. Tetrahedron Lett
45, 6291–6293 (2004)
57. Laubenstein, R., ¸
Serb, M.-D., Englert, U., Raabe, G., Braun, T., Braun, B.: Is it all in the hinge?
A kryptoracemate and three of its alternative racemic polymorphs of an aminonitrile. Chem.
Commun 52, 1214–1217 (2016)
E. R. T. Tiekink
48. Lewis, G.R., Steele, G., McBride L., Florence, A.J., Kennedy, A.R., Shankland, N., David,
W.I.F., Shankland, K., Teat, S.J.: Hydrophobic versus hydrophilic: ionic competition in
remacemide salt structures. Cryst. Growth Des. 5, 427–438 (2005)
49. Wardell, J.L., Wardell, S.M.S.V., Tiekink, E.R.T.: A kryptoracemic salt: 2-{[2,8bis(trifluoromethyl)quinolin-4-yl](hydroxy)methyl}piperidin-1-ium
(+)-3,3,3-trifluoro-2methoxy-2-phenylpropanoate. Acta Crystallogr. E57, 872–877 (2016)
50. Jotani, M.M., Wardell, J.L., Tiekink, E.R.T.: Crystal structure and Hirshfeld analysis of the
kryptoracemate: bis(mefloquinium) chloride p-fluorobenzenesulphonate. Z. Kristallogr. Cryst.
Mater. 231, 247–255 (2016)
51. Nevin, R.L.: A serious nightmare: psychiatric and neurologic adverse reactions to mefloquine
are serious adverse reactions. Pharmacol. Res. Perspect 5, e00328 (2017)
52. Engwerda, A.H.J., Maassen, R., Tinnemans, P., Meekes, H., Rutjes, F.P.J.T., Vlieg, E.: Attritionenhanced deracemization of the antimalaria drug mefloquine. Angew. Chem. Int. Ed 58, 1670–
1673 (2019)
53. Haleblian, J., McCrone, W.: Pharmaceutical applications of polymorphism. J. Pharm. Sci 58,
911–929 (1969)
54. Gavezzotti, A., Filippini, G.: Polymorphic forms of organic crystals at room conditions:
thermodynamic and structural implications. J. Am. Chem. Soc 117, 12299–12305 (1995)
55. Price, S.L.: Is zeroth order crystal structure prediction (CSP_0) coming to maturity? What
should we aim for in an ideal crystal structure prediction code? Faraday Discuss 211, 9–30
(2018)
56. Suresh, S., Periasamy, M.: Synthesis of cis-2-aryl-3-pyrrolidine carboxylic esters via diastereoselective cyclization of γ-imino esters using a TiCl 4 /Et 3 N reagent system. Tetrahedron Lett
45, 6291–6293 (2004)
57. Laubenstein, R., ¸
Serb, M.-D., Englert, U., Raabe, G., Braun, T., Braun, B.: Is it all in the hinge?
A kryptoracemate and three of its alternative racemic polymorphs of an aminonitrile. Chem.
Commun 52, 1214–1217 (2016)